Waldencast plc Warrant

Pomerantz LLP is investigating potential securities fraud claims against Waldencast plc following the company's November 24, 2025 announcement of significantly reduced financial guidance and substantial impairment charges. Waldencast downgraded its 2025 net revenue growth expectations from mid-teens to flat compared to 2024, and reduced adjusted ...

Obagi Medical presented new clinical research at the 2025 American Society for Dermatologic Surgery Annual Meeting, highlighting pivotal studies on hyaluronic acid fillers and a scalp serum, demonstrating promising results in midface augmentation and scalp health.

Obagi Medical introduces a new scalp serum clinically proven to reduce hair loss and promote fuller hair, targeting individuals experiencing hair thinning through a scientifically formulated product.

Waldencast reported mixed performance in H1 2025, with Obagi Medical and Milk Makeup experiencing growth challenges. The company acquired Novaestiq Corp., expanded into aesthetics, and initiated a strategic review to maximize shareholder value while adjusting full-year revenue and EBITDA guidance.

Waldencast has acquired Novaestiq Corp. and the U.S. rights to the Saypha® injectable hyaluronic acid gel line, expanding Obagi Medical's portfolio into dermal fillers and positioning the company at the intersection of skincare and aesthetic treatments.